Status:
NOT_YET_RECRUITING
AMPER Proof of Concept Study
Lead Sponsor:
University of Strathclyde
Collaborating Sponsors:
NHS Greater Glasgow and Clyde
Conditions:
Alzheimer's Dementia (AD)
Eligibility:
All Genders
50+ years
Phase:
NA
Brief Summary
The AMPER (Agent-based Memory Prosthesis to Encourage Reminiscing) system has been built to help people with Alzheimer's disease by improving their memory recall and quality of life. Alzheimer's often...
Eligibility Criteria
Inclusion
- \- Diagnosis of probable Alzheimer's disease of mild to moderate severity according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) and NINCS-ADRAD (National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association) criteria.
- Age 50 or older
- Sensory (visual and auditory), language, and physical abilities adequate to perform assessments (corrective aids allowed).
- ACE III score between 20 and 82 (inclusive) (or equivalent score on MMSE (between 14 and 24, based on Law et al., 20123 equivalence data) or MOCHA (between 14 and 24 (based on Pendleberry et al., 2011 equivalence data).
- Having a caregiver or family member who can attend all visits, perform assessments, and supervise administration of study.
Exclusion
- Medical records indicate AD patients with the visual variant or having colour vision deficits.
- Medical records indicate a CT or MRI within 24 months prior to screening that indicates a diagnosis other than probable Alzheimer's disease.
- Medical records indicate any significant neurological disease other than probable AD (e.g. Parkinson's disease, Huntington's disease, brain tumor, normal pressure hydrocephalus, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, history of stroke, or history of head injury requiring hospitalization).
- On review of medical records, no clinically significant abnormal findings on previous physical examination, medical history, or clinical laboratory results that would indicate an alternative diagnosis.
- Current history of major psychiatric disorder (e.g. Major depression) (as indicated on medical records)
- History of substance misuse (as indicated on medical records).
Key Trial Info
Start Date :
April 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06894953
Start Date
April 1 2025
End Date
February 28 2026
Last Update
March 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Strathclyde
Glasgow, United Kingdom